ASX:BLT

Stock Analysis Report

Executive Summary

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States.

Snowflake

Fundamentals

Flawless balance sheet and undervalued.

Share Price & News

How has Benitec Biopharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.9%

BLT

2.4%

AU Biotechs

0.4%

AU Market


1 Year Return

-66.9%

BLT

34.6%

AU Biotechs

9.8%

AU Market

Return vs Industry: BLT underperformed the Australian Biotechs industry which returned 34.6% over the past year.

Return vs Market: BLT underperformed the Australian Market which returned 9.8% over the past year.


Shareholder returns

BLTIndustryMarket
7 Day3.9%2.4%0.4%
30 Day8.2%6.8%-1.1%
90 Day0%12.6%-0.6%
1 Year-66.9%-66.9%36.2%34.6%16.1%9.8%
3 Year-42.5%-43.0%148.0%139.0%36.1%17.9%
5 Year-91.6%-91.7%232.1%210.5%49.4%15.7%

Price Volatility Vs. Market

How volatile is Benitec Biopharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Benitec Biopharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: BLT (A$0.05) is trading below our estimate of fair value (A$1.09)

Significantly Undervalued: BLT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BLT is good value based on its PE Ratio (3.3x) compared to the Biotechs industry average (28.7x).

PE vs Market: BLT is good value based on its PE Ratio (3.3x) compared to the Australian market (18.2x).


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate BLT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BLT is good value based on its PB Ratio (0.6x) compared to the AU Biotechs industry average (3x).


Next Steps

Future Growth

How is Benitec Biopharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

12.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Benitec Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Benitec Biopharma performed over the past 5 years?

24.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BLT has become profitable over the past 5 years, growing earnings by 24.3% per year.

Accelerating Growth: BLT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BLT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (16.2%).


Return on Equity

High ROE: BLT's Return on Equity (17.3%) is considered low.


Return on Assets

ROA vs Industry: BLT has a higher Return on Assets than the Biotechs industry average last year.


Return on Capital Employed

ROCE Improving: BLT's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Benitec Biopharma's financial position?


Financial Position Analysis

Short Term Liabilities: BLT's short term assets (A$26.7M) exceeds its short term liabilities (A$3.8M)

Long Term Liabilities: BLT has no long term liabilities


Debt to Equity History and Analysis

Debt Level: BLT is debt free.

Reducing Debt: BLT has not had any debt for past 5 years.

Debt Coverage: BLT has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: BLT has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: BLT has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if BLT's debt is covered by short term assets.


Next Steps

Dividend

What is Benitec Biopharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.4%markettop25%5.6%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate BLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BLT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if BLT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BLT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BLT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of Benitec Biopharma's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Jerel Banks 0

1.3yrs

Tenure

AU$1,293,248

Compensation

Dr. Jerel A. Banks, Ph.D., M.D. has been Chief Executive Officer of Benitec Biopharma Limited since June 26, 2018. Dr. Banks serves as Chief Investment Officer of NantVentures. Dr. Banks has been Senior Vi ...


CEO Compensation Analysis

Compensation vs. Market: Jerel has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the Australian market.

Compensation vs Earnings: Jerel's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.3yrs

Average Tenure

Experienced Management: BLT's management team is considered experienced (2.3 years average tenure).


Board Age and Tenure

4.0yrs

Average Tenure

Experienced Board: BLT's board of directors are considered experienced (4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Jerel Banks

    CEO & Executive Chairman

    • Tenure: 1.3yrs
    • Compensation: AU$1.29m
  • Michael Graham

    Head of Discovery & Founding Scientist

    • Tenure: 4.3yrs
    • Compensation: AU$217.06k
  • Megan Boston

    Head of Operations - Australia & Executive Director

    • Tenure: 3.2yrs
    • Compensation: AU$394.02k
  • Craig Lewis

    Chief Medical Adviser

    • Tenure: 5.6yrs
  • Claudia Kloth

    Senior Vice President of Manufacturing

    • Tenure: 0yrs
  • Oliver Kidd

    Company Secretary

    • Tenure: 1.3yrs
  • Bryan Dulhunty

    Chief Financial Officer

    • Tenure: 3.2yrs

Board Members

  • Peter Francis (63yo)

    Non-Executive Director

    • Tenure: 13.7yrs
    • Compensation: AU$76.65k
  • Jerel Banks

    CEO & Executive Chairman

    • Tenure: 1.3yrs
    • Compensation: AU$1.29m
  • Megan Boston

    Head of Operations - Australia & Executive Director

    • Tenure: 3.2yrs
    • Compensation: AU$394.02k
  • J. Buchi

    Non-Executive Director

    • Tenure: 6.5yrs
    • Compensation: AU$76.65k
  • Geoffrey McCaughan

    Member of Hepatology Clinical Advisory Board

    • Tenure: 4yrs
  • Harry Janssen

    Member of Hepatology Clinical Advisory Board

    • Tenure: 4yrs
  • Keyur Patel

    Member of Hepatology Clinical Advisory Board

    • Tenure: 4yrs
  • George Dickson

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0yrs

Company Information

Benitec Biopharma Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Benitec Biopharma Limited
  • Ticker: BLT
  • Exchange: ASX
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$16.591m
  • Shares outstanding: 313.03m
  • Website: https://www.benitec.com

Number of Employees


Location

  • Benitec Biopharma Limited
  • 114 William Street
  • Level 14
  • Melbourne
  • Victoria
  • 3000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BLTASX (Australian Securities Exchange)YesOrdinary SharesAUAUDMay 2002
BJ9DB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 2002
BNIK.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMay 2002
BLTCHIA (Chi-X Australia)YesOrdinary SharesAUAUDMay 2002
BNTCNasdaqCM (Nasdaq Capital Market)SPONS ADR NEWUSUSDJul 2012
BJ91DB (Deutsche Boerse AG)SPONS ADR NEWDEEURJul 2012

Biography

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Austra ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 10:31
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.